Table 3.
Authors | Publication Country year | Country | Design | Controls | Number | Vitamin D dose | Curative effect | Safety | Jadad scores | References |
---|---|---|---|---|---|---|---|---|---|---|
Zendedel et al | 2015 | Iran | Single-center, double-blind, Placebo and randomized | Placebo | 44 vs 44 | Oral doses of 100,000 IU per month for 6 months | Decreased COPD exacerbation and improved FEV1in the patients with severe COPD | NA | 3 | 41 |
Martineau et al | 2015 | UK | Multicenter, double-blind, and randomized | Placebo | 118 vs 122 | Six bimonthly oral doses of 120,000 IU | Effective against moderate or severe exacerbation in COPD patients with 25(OH)D deficiency | No serious adverse event | 5 | 38 |
Bjerk et al | 2013 | USA | Single center and pilot randomized | Placebo | 18 vs 18 | Oral doses of 2,000 IU daily for 6 weeks | No discernible effect on a simple measure of physical performance | NA | 1 | 40 |
Hornikx et al | 2012 | Belgium | Double-blind and randomized | Placebo | 25 vs 25 | A monthly dose of 100,000 IU for 1 year | Improvement in inspiratory muscle strength and maximal oxygen uptake | NA | 4 | 39 |
Lehouck et al | 2012 | Belgium | Randomized | Placebo | 91 vs 91 | A monthly dose of 100,000 IU for 1 year | Reduced exacerbation in COPD patients with 25(OH)D deficiency | Four with mild and asymptomatic hypercalcemia | 4 | 9 |
Abbreviations: 25(OH)D, 25-hydroxyvitamin D; FEV1, forced expiratory volume in 1 second; NA, not applicable.